Pressmeddelande -
New ETVAX® data was presented during VASE, an international gathering dedicated to develop Shigella and ETEC vaccines
During three days in Washington, the top minds in the enteric vaccine field met to share the latest research and ideas toward making enteric vaccines a reality to advance global health. Scandinavian Biopharma was playing a key role sharing important research and development advancements.
The Vaccines Against Shigella and Enterotoxigenic Escherichia coli (VASE) Conference brings together hundreds of scientists, public health professionals, immunization leaders, vaccine industry representatives, international donors, and other experts around the globe.
Dr Nils Carlin from Scandinavian Biopharma gave an update of the vaccine formulation for licensure, an overview over the accomplished clinical program and over the planned efficacy trials in phase 3. Dr. Nsofwa Sukwa, from the Centre for Infectious Disease Research in Zambia, presented results from our completed phase 1 age-descending study in Zambia where ETVAX ® was shown safe, tolerable, and immunogenic in Zambian adults and children.
PI Dr Jahangir Hossain, Medical Research Council Unit The Gambian at the London School of Hygiene & Tropical Medicine, and Professor Tom Wierzba, Wake Forest University, presented data from our large Phase IIb trial in The Gambia where all participants recently received the third and final vaccination dose.
Dr Firdausi Qadri, icddr,b in Dhaka, shared surveillance data as well as data on the impact of ETEC and cholera epidemics from Bangladesh. Cynthia Mubanga, Research fellow at Centre for Infectious Disease Research in Zambia, presented promising cross-reactivity of the ETVAX® vaccine-induced antibodies to diarrhoeagenic Escherichia coli specific antigens using microarray analysis.
This is really a conference designed to spark innovation. Children are still dying and facing long-term health consequences due to this preventable illness, and new interventions are urgently needed. For us, it is extremely important to participate in the scientific debate to accelerate the momentum for research and development in the enteric vaccine field, says Björn Sjöstrand CEO of Scandinavian Biopharma.
Ämnen
Kategorier
About Scandinavian Biopharma
Scandinavian Biopharma is a research-based specialty biopharma company determined to give people all over the world a longer and better life. Together with researchers at the University of Gothenburg and the international non-profit organization PATH, Scandinavian Biopharma is developing the first vaccine against ETEC which causes diarrhoea in both travellers and endemic populations.
The development project is mainly funded by the EDCTP programme, which is supported under Horizon 2020, the European Union’s (EU) Framework Programme for Research and Innovation, as well as by PATH and the U.S. Army (USAMMDA).
Scandinavian Biopharma also acts as a distributor for a wide range of specialty biopharma products in Europe with a focus on vaccines and immunoglobulins.
About ETEC
Enterotoxigenic Escherichia coli, or ETEC, is a major cause of bacterial diarrhoeal disease. ETEC infections are particularly common in low- and middle-income countries (LMIC). In children younger than 5 years, it has been estimated that 1.7 billion episodes of diarrhoea occur annually. ETEC represents a major cause of these episodes and accounts for approximately 400 000 deaths among children living in LMICs. In addition, diarrhoea is associated with an increased risk of stunting (i.e. impaired growth and development). Stunting affects cognitive development which might determine a child’s ability to learn, their educational attainment, and future earnings and it also puts children at risk due to other severe infectious diseases.
ETEC is also the leading cause of travellers’ diarrhoea, affecting more than 35 million travellers every year.
About ETVAX®
To date, no vaccine against ETEC exists and ETVAX® is the only ETEC vaccine candidate in late-stage development. The strong immunogenicity and safety data, as well as the promising field efficacy data, clearly distinguish ETVAX® as the lead vaccine candidate against ETEC. Successful development of this vaccine will address a huge unmet medical need for children in LMICs as well as for travellers.
